Tranexamic Acid Reduce Blood Loss in Meningioma Resection
Status:
Not yet recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
In neurosurgical setting, a large sample size trials of tranexamic acid (TXA) has been
limited to TBI and SAH.
The evidence of TXA in brain tumor was scarce. A few case reports support the role of TXA in
brain tumor patients with significant intraoperative bleeding and difficult achieving
hemostasis. To prove the benefit of TXA for an attenuation of blood loss in brain tumor
patients, research with a larger sample size is required. This prospective, randomized
double-blind controlled study will be conducted to evaluate the effect of TXA in reducing
blood loss and blood transfusion in patients with intracranial meningiomas, diameter > 5 cm
in at least 2 dimensions from the latest radiographic findings.